Nitric Oxide and Drosophila Development
Total Page:16
File Type:pdf, Size:1020Kb

Load more
Recommended publications
-
List of Abbreviations
List of Abbreviations 1,3BPGA 1,3-Bisphospho-D-glycerate 10-formyl THF 10-Formyltetrahydrofolate 2PG 2-phospho-D-glycerate 3PG 3-phospho-D-glycerate 3PPyr 3-phosphonooxypyruvate 3PSer 3-phosphoserine 6PDG 6-phospho-D-gluconate 6Pgl glucono-1,5-lactone-6-phosphate AcAcACP acetoacetyl-ACP AcAcCoA acetoacetyl-CoA AcACP acetyl-ACP AcCoA acetyl-CoA ACP acyl carrier protein ADP adenosine 5'-diphosphate AKG alpha-ketoglutarate Ala alanine AMP adenosine 5'-monophosphate Arg arginine ArgSuc argininosuccinate Asn asparagine Asp aspartate ATP adenosine 5'-triphosphate CDP cytidine 5'-diphosphate Chol cholesterol Ci citrulline Cit citrate CMP cytidine 5'-monophosphate CO2 carbon dioxide CoA coenzyme A CP carbamoyl-phosphate CTP cytidine 5'-triphosphate Cytc-ox ferricytochrome c Cytc-red ferrocytochrome c dADP 2'-deoxyadenosine 5'-diphosphate dAMP 2'-deoxyadenosine 5'-monophosphate dCDP 2'-deoxycytosine 5'-diphosphate dCMP 2'-deoxycytosine 5'-monophosphate dGDP 2'-deoxyguanosine 5'-diphosphate dGMP 2'-deoxyguanosine 5'-monophosphate DHAP dihydroxyacetone phosphate DHF 7,8-Dihydrofolate dTMP 2'-Deoxythymidine-5'-monophosphate dUDP 2'-Deoxyuridine-5'-diphosphate dUMP 2'-Deoxyuridine-5'-monophosphate Ery4P erythrose-4-phosphate F16BP fructose 1,6-bisphosphate F6P fructose 6-phosphate FAD flavin adenine dinucleotide FADH2 flavin adenine dinucleotide reduced for formate fPP farnesyl diphosphate Fum fumarate G6P glucose 6-phosphate GA guanidinoacetate GA3P glyceraldehyde 3-phosphate GDP guanosine 5'-diphosphate Glc glucose Gln glutamine Glu glutamate GluSA -
Reduced Renal Methylarginine Metabolism Protects Against Progressive Kidney Damage
BASIC RESEARCH www.jasn.org Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage † James A.P. Tomlinson,* Ben Caplin, Olga Boruc,* Claire Bruce-Cobbold,* Pedro Cutillas,* † ‡ Dirk Dormann,* Peter Faull,* Rebecca C. Grossman, Sanjay Khadayate,* Valeria R. Mas, † | Dorothea D. Nitsch,§ Zhen Wang,* Jill T. Norman, Christopher S. Wilcox, † David C. Wheeler, and James Leiper* *Medical Research Council Clinical Sciences Centre, Imperial College, London, United Kingdom; †Centre for Nephrology, UCL Medical School Royal Free, London, United Kingdom; ‡Translational Genomics Transplant Laboratory, Transplant Division, Department of Surgery, University of Virginia, Charlottesville, Virginia; §Department of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom; and |Hypertension, Kidney and Vascular Research Center, Georgetown University, Washington, DC ABSTRACT Nitric oxide (NO) production is diminished in many patients with cardiovascular and renal disease. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of NO synthesis, and elevated plasma levels of ADMA are associated with poor outcomes. Dimethylarginine dimethylaminohydrolase-1 (DDAH1) is a methylarginine- metabolizing enzyme that reduces ADMA levels. We reported previously that a DDAH1 gene variant associated with increased renal DDAH1 mRNA transcription and lower plasma ADMA levels, but counterintuitively, a steeper rate of renal function decline. Here, we test the hypothesis that reduced renal-specific -
By Norepinephrine and Inactivated by NO and Cgmp (Medial Basal Hypothalami/Luteinizing Hormone-Releasing Hormone/Camp/Arginine/Nitroarginine Methyl Ester) G
Proc. Natl. Acad. Sci. USA Vol. 93, pp. 4246-4250, April 1996 Physiology Nitric oxide synthase content of hypothalamic explants: Increased by norepinephrine and inactivated by NO and cGMP (medial basal hypothalami/luteinizing hormone-releasing hormone/cAMP/arginine/nitroarginine methyl ester) G. CANTEROS*, V. RErroRI*, A. GENARO*, A. SUBURO*, M. GIMENO*, AND S. M. MCCANNtt *Centro de Estudios Farmacologicos y Botanicos, Consejo Nacional de Investigaciones Cientificas y Tecnicas, Serrano 665, 1414 Buenos Aires, Argentina; and tPennington Biomedical Research Center, Louisiana State University, 6400 Perkins Road, Baton Rouge, LA 70808-4124 Contributed by S. M. McCann, December 26, 1995 ABSTRACT Release of luteinizing hormone (LH)- pituitary gland. There it releases LH, which induces ovulation releasing hormone (LHRH), the hypothalamic peptide that and ovarian steroid secretion in females and testosterone controls release of LH from the adenohypophysis, is con- secretion in males (3). Since NO controls LHRH release in the trolled by NO. There is a rich plexus of nitric oxide synthase arcuate nucleus-median eminence region, where axons of (NOS)-containing neurons and fibers in the lateral median LHRH neurons terminate on the portal capillaries (2), we eminence, intermingled with terminals of the LHRH neurons. expected to find NOergic neurons in this region. Indeed, in the To study relations between NOS and LHRH in this brain present study we found a large number of NOergic cell bodies region, we measured NOS activity in incubated medial basal and fibers in the arcuate-median eminence region. hypothalamus (MBH). NOS converts [l4C]arginine to equimo- This study was initiated to determine if we could measure lar quantities of [14C]citrulline plus NO, which rapidly decom- NOS activity in incubated medial basal hypothalami (MBHs) poses. -
Triphosphate Accumulation, DNA Damage, and Growth Inhibition Following Exposure to CB3717 and Dipyridamole Nicola J
(CANCER RESEARCH 51. 2346-2352, May I. 1991) Mechanism of Cell Death following Thymidylate Synthase Inhibition: 2'-Deoxyuridine-5'-triphosphate Accumulation, DNA Damage, and Growth Inhibition following Exposure to CB3717 and Dipyridamole Nicola J. Curtin,1 Adrian L. Harris, and G. Wynne Aherne Cancer Research L'nil, Medical School, University of Newcastle upon Tyne, Newcastle upon Tyne [N. J. C.J; Imperial Cancer Research Fund Clinical Oncology Unit, Churchill Hospital, Headington, Oxon ¡A.L. H.]; Department of Biochemistry, University of Surrey, Guildford, Surrey [G. W. A.], England ABSTRACT but one hypothesis, based on the study of bacterial mutants (3- The thymidylate synthasc inhibitor /V'°-propargyl-5,8-dideazafolic 5), is that TS inhibition leads not only to a reduction in dTTP levels but also, as dUMP accumulates behind the block, to the acid (CB3717) inhibits the growth of human lung carcinoma A549 cells. formation of dUTP. The levels of dUTP eventually overwhelm The cytotoxicity of CB3717 is potentiated by the nucleoside transport inhibitor dipyridamole (DP), which not only inhibits the uptake and dUTPase (the enzyme which breaks down dUTP to dUMP) therefore salvage of thymidine but also inhibits the efflux of deoxyuridine, and the levels of dUTP increase. DNA polymerase can utilize thereby enhancing the intracellular accumulation of deoxyuridine nucleo- dUTP and dTTP with equal efficiency (6), such that uracil is tides. Measurement of intracellular deoxyuridine triphosphate (dUTP) misincorporated into DNA. Uracil in DNA is excised rapidly pools, by sensitive radioimmunoassay, demonstrated a large increase in by uracil glycosylase, leaving an apyrimidinic site. During repair response to CB3717, in a dose- and time-related manner, and this of apyrimidinic sites, in the presence of unbalanced dUTP/ accumulation was enhanced by coincubation with DP. -
S-Nitrosylation Drives Cell Senescence and Aging in Mammals By
S-nitrosylation drives cell senescence and aging in PNAS PLUS mammals by controlling mitochondrial dynamics and mitophagy Salvatore Rizzaa,1, Simone Cardacib,1, Costanza Montagnaa,c,1, Giuseppina Di Giacomod,2, Daniela De Zioa, Matteo Bordid, Emiliano Maiania, Silvia Campellod,e, Antonella Borrecaf, Annibale A. Pucag,h, Jonathan S. Stamleri,j, Francesco Cecconia,d,k, and Giuseppe Filomenia,d,3 aDanish Cancer Society Research Center, Center for Autophagy, Recycling and Disease, 2100 Copenhagen, Denmark; bDivision of Genetics and Cell Biology, Institute for Research and Health Care San Raffaele (IRCCS) Scientific Institute, 20132 Milan, Italy; cInstitute of Sports Medicine Copenhagen, Bispebjerg Hospital, 2400 Copenhagen, Denmark; dDepartment of Biology, Tor Vergata University, 00133 Rome, Italy; eIRCCS Fondazione Santa Lucia, 00146 Rome, Italy; fInstitute of Cellular Biology and Neuroscience, National Research Council, 00143 Rome, Italy; gCardiovascular Research Unit, IRCCS Multimedica, 20138 Milan, Italy; hDipartimento di Medicina e Chirurgia, University of Salerno, 84084 Fisciano Salerno, Italy; iInstitute for Transformative Molecular Medicine, Case Western Reserve University, Cleveland, OH 44106; jHarrington Discovery Institute, University Hospitals Case Medical Center, Cleveland, OH 44106; and kDepartment of Pediatric Hematology and Oncology, IRCCS Bambino Gesù Children’s Hospital, 00146 Rome, Italy Edited by Solomon H. Snyder, Johns Hopkins University School of Medicine, Baltimore, MD, and approved March 1, 2018 (received for review January 9, 2018) S-nitrosylation, a prototypic redox-based posttranslational modifi- found in experimental models of aging, supporting the idea that cation, is frequently dysregulated in disease. S-nitrosoglutathione GSNOR preserves cellular function. reductase (GSNOR) regulates protein S-nitrosylation by function- The free radical theory of aging postulates that oxidative ing as a protein denitrosylase. -
Cancer Science Standard Abbreviations List
Cancer Science Standard Abbreviations List Common abbreviations, acronyms and short names are listed below. These shortened forms can be used without definition in articles published in Cancer Science. The same form is used in the plural. 7-AAD 7-amino-actinomycin D (stain) ES cell embryonic stem cell Ab antibody EST expressed sequence tag ADP adenosine 5′-diphosphate FACS fluorescence-activated cell sorter dADP 2′-deoxyadenosine 5′-diphosphate FBS fetal bovine serum AIDS acquired immunodeficiency syndrome FCS fetal calf serum Akt protein kinase B FDA Food and Drug Administration AML acute myelogenous leukemia FISH fluorescence in situ hybridization AMP adenosine 5′-monophosphate FITC fluorescein isothiocyanate dAMP 2′-deoxyadenosine 5′-monophosphate FPLC fast protein liquid chromatography ANOVA analysis of variance FRET fluorescence resonance energy transfer ATCC American Type Culture Collection GAPDH glyceraldehyde-3-phosphate dehydrogenase ATP adenosine 5′-triphosphate GDP guanosine 5′-diphosphate dATP 2′-deoxyadenosine 5′-triphosphate dGDP 2′-deoxyguanosine 5′-diphosphate beta-Gal, β-Gal beta-galactosidase GFP green fluorescent protein bp base pair(s) GMP guanosine 5′-monophosphate BrdU 5-bromodeoxyuridine dGMP 2′-deoxyguanosine 5′-monophosphate BSA bovine serum albumin GST glutathione S-transferase CCK-8 Cell Counting Kit-8 (tradename) GTP guanosine 5′-triphosphate CDP cytidine 5′-diphosphate dGTP 2′-deoxyguanosine 5′-triphosphate cCDP 2′-deoxycytidine 5′-diphosphate HA hemagglutinin CHAPS 3-[(3-cholamidopropyl)dimethylamino]-1- -
Proceeding of the Symposium NITRIC OXIDE Basic Regulations And
Proceeding of the Symposium NITRIC OXIDE Basic Regulations and Pharmacological Interventions September 21-24, 2005, Tucepi, Croatia Abstracts are presented in the alphabetical order of the first author names and are printed without editing in the submitted form. The Editorial Office of Physiological Research disclaims any responsibility for errors that may have been made in abstracts submitted by the authors. Vol. 55 Physiol. Res. 2006 1P VASODILATORY RESPONS ES UNDER HYPOXIC responses of myocardium to NOD and in adaptive responses of these CONDITION: ROLE OF PGI2 AND NO hearts to ischemic stress. The results point also to the possible I. Juránek, V. Bauer, J. Donnerer1, F. Lembeck1, B.A. Peskar1 relationship between ERK pathway and activation of eNOS and/or Institute of Experimental Pharmacology, Slovak Academy of Sciences, tissue MMP-2. Bratislava, Slovakia; 1Institute of Experimental and Clinical 1. Strohm et. al., J. Cardiovasc. Pharmacol. 2000, 36:218-229 Pharmacology, Medical University, Graz, Austria. Supported by VEGA SR No 2/3123/25, 2/5110/25, APVT 51-013802, SP51/0280900/ 0280901, SP51/028000/0280802. Aim of the present study was to test hypothesis that low availability of oxygen in hypoxic tissue should inhibit oxygenation of arachidonic acid and thereby result in inhibition of eicosanoid synthesis in vivo. Perfusion of the isolated rabbit ear with normoxic or hypoxic medium DUAL ROLE OF NO IN SUSCEPTIBILITY TO ISCHEMIA/ was applied. Eicosanoid biosynthesis and functional responses of the REPERFUSION INJURY IN THE RAT HEART vascular bed were followed. Simultaneous recording of prostaglandin I2 E. Andelová, M. Pintérová, P. Šimoncíková, M. Barancík, M. release and peripheral resistance of t he preparation revealed that lack of Ondrejcáková, *O. -
Viagra, INN-Sildenafil
SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion for the approval of VIAGRA. This scientific discussion has been updated until 1 December 2002. For information on changes after this date please refer to module 8B. 1. Introduction Male erectile dysfunction (ED) has been defined as the inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance as part of the overall process of male sexual function (NIH Consensus Conference, 1993). ED can have a profound impact on the quality of life with subjects often reporting increased anxiety, loss of self-esteem, lack of self-confidence, tension and difficulty in the relationship with their partner. The prevalence of ED has been found to be associated with age. Complete ED has an estimated prevalence of about 5% in men aged 40 years to 15% at age 70 years. It should be recognised that desire, orgasmic capacity and ejaculatory capacity may be intact even in the presence of erectile dysfunction or may be deficient to some extent and contribute to the sense of inadequate sexual function. The term impotence, together with its pejorative implications, is less precise and should not be used. The degree of erectile dysfunction can vary and may range from a partial decrease in penile rigidity to complete erectile failure and the frequency of these failures may also range from “a few times a year” to “usually unable to obtain an erection”. ED is often multifactorial in etiology (organic, psychogenic, or mixed). Sometimes ED is related to stress problems with the sexual partner or transient psychological factors. -
Distribution of Nucleosides in Populations of Cordyceps Cicadae
Molecules 2014, 19, 6123-6141; doi:10.3390/molecules19056123 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Article Distribution of Nucleosides in Populations of Cordyceps cicadae Wen-Bo Zeng 1, Hong Yu 1,*, Feng Ge 2, Jun-Yuan Yang 1, Zi-Hong Chen 1, Yuan-Bing Wang 1, Yong-Dong Dai 1 and Alison Adams 3 1 Yunnan Herbal Laboratory, Institute of Herb Biotic Resources, Yunnan University, Kunming 650091, Yunnan, China; E-Mails: [email protected] (W.-B.Z.); [email protected] (J.-Y.Y.); [email protected] (Z.-H.C.); [email protected] (Y.-B.W.); [email protected] (Y.-D.D.) 2 Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, Yunnan, China; E-Mail: [email protected] 3 Department of Biological Sciences, College of Engineering, Forestry and Natural Science, Northern Arizona University, Flagstaff, AZ 86011-5640, USA; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected] or [email protected]; Tel.: +86-137-006-766-33; Fax: +86-871-650-346-55. Received: 15 January 2014; in revised form: 25 April 2014 / Accepted: 5 May 2014 / Published: 14 May 2014 Abstract: A rapid HPLC method had been developed and used for the simultaneous determination of 10 nucleosides (uracil, uridine, 2'-deoxyuridine, inosine, guanosine, thymidine, adenine, adenosine, 2'-deoxyadenosine and cordycepin) in 10 populations of Cordyceps cicadae, in order to compare four populations of Ophicordyceps sinensis and one population of Cordyceps militaris. Statistical analysis system (SAS) 8.1 was used to analyze the nucleoside data. -
Deoxyadenosine Triphosphate As a Mediator of Deoxyguanosine Toxicity in Cultured T Lymphoblasts
Deoxyadenosine triphosphate as a mediator of deoxyguanosine toxicity in cultured T lymphoblasts. G J Mann, R M Fox J Clin Invest. 1986;78(5):1261-1269. https://doi.org/10.1172/JCI112710. Research Article The mechanism by which 2'-deoxyguanosine is toxic for lymphoid cells is relevant both to the severe cellular immune defect of inherited purine nucleoside phosphorylase (PNP) deficiency and to attempts to exploit PNP inhibitors therapeutically. We have studied the cell cycle and biochemical effects of 2'-deoxyguanosine in human lymphoblasts using the PNP inhibitor 8-aminoguanosine. We show that cytostatic 2'-deoxyguanosine concentrations cause G1-phase arrest in PNP-inhibited T lymphoblasts, regardless of their hypoxanthine guanine phosphoribosyltransferase status. This effect is identical to that produced by 2'-deoxyadenosine in adenosine deaminase-inhibited T cells. 2'-Deoxyguanosine elevates both the 2'-deoxyguanosine-5'-triphosphate (dGTP) and 2'-deoxyadenosine-5'-triphosphate (dATP) pools; subsequently pyrimidine deoxyribonucleotide pools are depleted. The time course of these biochemical changes indicates that the onset of G1-phase arrest is related to increase of the dATP rather than the dGTP pool. When dGTP elevation is dissociated from dATP elevation by coincubation with 2'-deoxycytidine, dGTP does not by itself interrupt transit from the G1 to the S phase. It is proposed that dATP can mediate both 2'-deoxyguanosine and 2'-deoxyadenosine toxicity in T lymphoblasts. Find the latest version: https://jci.me/112710/pdf Deoxyadenosine Triphosphate as a Mediator of Deoxyguanosine Toxicity in Cultured T Lymphoblasts G. J. Mann and R. M. Fox Ludwig Institute for Cancer Research (Sydney Branch), University ofSydney, Sydney, New South Wales 2006, Australia Abstract urine of PNP-deficient individuals, with elevation of plasma inosine and guanosine and mild hypouricemia (3). -
CFA As a Clinically Translatable Probe for PET Imaging of Deoxycytidine Kinase Activity
[18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity Woosuk Kima,b,1, Thuc M. Lea,b,1, Liu Weia,b, Soumya Poddara,b, Jimmy Bazzya,b, Xuemeng Wanga,b, Nhu T. Uonga,b, Evan R. Abta,b, Joseph R. Capria,b, Wayne R. Austinc, Juno S. Van Valkenburghb,d, Dalton Steeleb,d, Raymond M. Gipsond, Roger Slavika,b, Anthony E. Cabebea,b, Thotsophon Taechariyakula,b, Shahriar S. Yaghoubie, Jason T. Leea,f, Saman Sadeghia,b, Arnon Lavieg, Kym F. Faulla,b,h,i, Owen N. Wittea,j,k,l, Timothy R. Donahuea,b,m, Michael E. Phelpsa,f,2, Harvey R. Herschmana,b,n, Ken Herrmanna,b, Johannes Czernina,b, and Caius G. Radua,b,2 aDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095; bAhmanson Translational Imaging Division, University of California, Los Angeles, CA 90095; cAbcam, Cambridge, MA 02139-1517; dDepartment of Chemistry and Biochemistry, University of California, Los Angeles, CA 90095; eCellSight Technologies, Inc., San Francisco, CA 94107; fCrump Institute for Molecular Imaging, University of California, Los Angeles, CA 90095; gDepartment of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, IL 60607; hThe Pasarow Mass Spectrometry Laboratory, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA 90095; iDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA 90095; jDepartment of Microbiology, Immunology, & Molecular Genetics, University of California, Los Angeles, CA 90095; kHoward Hughes Medical Institute, University of California, Los Angeles, CA 90095; lEli & Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, CA 90095; mDepartment of Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA 90095; and nDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, CA 90095 Contributed by Michael E. -
Developmental Disorder Associated with Increased Cellular Nucleotidase Activity (Purine-Pyrimidine Metabolism͞uridine͞brain Diseases)
Proc. Natl. Acad. Sci. USA Vol. 94, pp. 11601–11606, October 1997 Medical Sciences Developmental disorder associated with increased cellular nucleotidase activity (purine-pyrimidine metabolismyuridineybrain diseases) THEODORE PAGE*†,ALICE YU‡,JOHN FONTANESI‡, AND WILLIAM L. NYHAN‡ Departments of *Neurosciences and ‡Pediatrics, University of California at San Diego, La Jolla, CA 92093 Communicated by J. Edwin Seegmiller, University of California at San Diego, La Jolla, CA, August 7, 1997 (received for review June 26, 1997) ABSTRACT Four unrelated patients are described with a represent defects of purine metabolism, although no specific syndrome that included developmental delay, seizures, ataxia, enzyme abnormality has been identified in these cases (6). In recurrent infections, severe language deficit, and an unusual none of these disorders has it been possible to delineate the behavioral phenotype characterized by hyperactivity, short mechanism through which the enzyme deficiency produces the attention span, and poor social interaction. These manifesta- neurological or behavioral abnormalities. Therapeutic strate- tions appeared within the first few years of life. Each patient gies designed to treat the behavioral and neurological abnor- displayed abnormalities on EEG. No unusual metabolites were malities of these disorders by replacing the supposed deficient found in plasma or urine, and metabolic testing was normal metabolites have not been successful in any case. except for persistent hypouricosuria. Investigation of purine This report describes four unrelated patients in whom and pyrimidine metabolism in cultured fibroblasts derived developmental delay, seizures, ataxia, recurrent infections, from these patients showed normal incorporation of purine speech deficit, and an unusual behavioral phenotype were bases into nucleotides but decreased incorporation of uridine.